Durvalumab and Tremelimumab in Resectable HCC
Durvalumab and Tremelimumab in Resectable HCC
Recruiting · NCT05440864 · Registry updated 2024-10-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Durvalumab and Tremelimumab in Resectable HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Phase 2 | 2024-10-10 | NCT05440864 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Clinica Universidad de Navarra, Universidad de Navarra | 41 |
| University Health Network, Toronto | 417 |
| University of Milan | 55 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Clinica Universidad de Navarra | Pamplona | Spain | 36 |
| University Health Network | Toronto | Canada | 52 |
| University of Milan | Milan | Italy | 1 |